Press Releases

YEAR
Toggle Summary Nabriva Therapeutics Reports Fourth Quarter and Year End 2019 Financial Results and Recent Corporate Highlights
- Prioritizing community opportunity for oral XENLETA given broad reimbursement coverage- - Reducing balance sheet risk through early paydown of a substantial portion of Hercules loan- - Pursuing options to provide lefamulin to patients with coronavirus with secondary bacterial infections-
View HTML
Toggle Summary Nabriva Therapeutics to Report 2019 Financial Results and Recent Corporate Highlights on March 12, 2020
DUBLIN, Ireland , March 10, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its fourth quarter and full
View HTML
Toggle Summary Nabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , March 02, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options
View HTML
Toggle Summary Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , Feb. 05, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options
View HTML
Toggle Summary Nabriva Therapeutics Receives FDA Acknowledgement of New Drug Application Resubmission for Intravenous CONTEPO™ (fosfomycin) for Injection
PDUFA action date set for June 19, 2020 DUBLIN, Ireland , Jan. 08, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a commercial-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, announced that the U.S.
View HTML
Toggle Summary Nabriva Therapeutics Announces $20 Million Registered Direct Offering
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Dec. 20, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has entered
View HTML
Toggle Summary Nabriva Therapeutics Resubmits New Drug Application for Intravenous CONTEPO™ (fosfomycin) for Injection
-Nabriva anticipates a six-month review period by the Food and Drug Administration -CONTEPO is a potential first-in-class intravenous antibiotic in U.S. for the treatment of complicated urinary tract infections DUBLIN, Ireland , Dec. 20, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:
View HTML
Toggle Summary Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , Dec. 02, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options
View HTML
Toggle Summary Nabriva Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Nov. 21, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Gary Sender Chief
View HTML
Toggle Summary Nabriva Therapeutics Commends the CDC on the 2019 Antibiotic Resistance Threats Report, Highlighting the Need for New Antibiotics Aligned with Antibiotic Stewardship
S. pneumoniae continues to be designated by the CDC as “Serious Threat” underscoring need for rapid detection and prevention strategies, particularly in community setting   XENLETA™ has a novel mechanism of action that is different than all other antibiotics, has been shown to be associated with a
View HTML

For Media Inquiries

E-mail: PR@nabriva.com


For Investor Relations

E-mail: IR@nabriva.com